TY - JOUR
T1 - Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis
AU - Harada, Kazuto
AU - Yamashita, Kohei
AU - Iwatsuki, Masaaki
AU - Baba, Hideo
AU - Ajani, Jaffer A.
N1 - Funding Information:
This paper was not funded. The authors would like to thank H. Nikki March from Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing a draft of this manuscript.
Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Introduction: Gastric adenocarcinoma (GAC) is one of the most aggressive malignancies worldwide and has a poor prognosis. Multidisciplinary therapies are used in its treatment, but the prognosis for GAC patients with peritoneal metastases (PM) remains poor and there is no effective established approach. Areas covered: This review summarizes the results of recent clinical studies and recent advances in the management, including surgery, chemotherapy, targeted therapy, and immunotherapy. In this review, keywords were searched in combination with ‘peritoneal carcinomatosis’ and ‘gastric cancer’ in PubMed, and then studies that evaluated peritoneal carcinomatosis associated with gastric cancer were identified through reading them. Several studies were quoted at second hand. Despite recent advances in therapeutic approaches such as systemic chemotherapy, immunotherapy, intraperitoneal chemotherapy, debulking surgery, thermal hyperthermic intraperitoneal chemotherapy, pressurized intraperitoneal aerosol chemotherapy, immunotherapy, and best supportive therapy, further studies are necessary. This review also summarizes molecular biology of GAC patients with PM. Expert opinion: Each modality is advancing and some have shown therapeutic effects, but none have become standard treatments that exhibit remarkable effects. To improve the prognosis of GAC patients with PM, large-scale clinical trials and further basic research are required.
AB - Introduction: Gastric adenocarcinoma (GAC) is one of the most aggressive malignancies worldwide and has a poor prognosis. Multidisciplinary therapies are used in its treatment, but the prognosis for GAC patients with peritoneal metastases (PM) remains poor and there is no effective established approach. Areas covered: This review summarizes the results of recent clinical studies and recent advances in the management, including surgery, chemotherapy, targeted therapy, and immunotherapy. In this review, keywords were searched in combination with ‘peritoneal carcinomatosis’ and ‘gastric cancer’ in PubMed, and then studies that evaluated peritoneal carcinomatosis associated with gastric cancer were identified through reading them. Several studies were quoted at second hand. Despite recent advances in therapeutic approaches such as systemic chemotherapy, immunotherapy, intraperitoneal chemotherapy, debulking surgery, thermal hyperthermic intraperitoneal chemotherapy, pressurized intraperitoneal aerosol chemotherapy, immunotherapy, and best supportive therapy, further studies are necessary. This review also summarizes molecular biology of GAC patients with PM. Expert opinion: Each modality is advancing and some have shown therapeutic effects, but none have become standard treatments that exhibit remarkable effects. To improve the prognosis of GAC patients with PM, large-scale clinical trials and further basic research are required.
KW - Gastric adenocarcinoma
KW - intraperitoneal therapy
KW - peritoneal dissemination
UR - http://www.scopus.com/inward/record.url?scp=85125733225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125733225&partnerID=8YFLogxK
U2 - 10.1080/17512433.2022.2044790
DO - 10.1080/17512433.2022.2044790
M3 - Review article
C2 - 35184625
AN - SCOPUS:85125733225
SN - 1751-2433
VL - 15
SP - 43
EP - 49
JO - Expert Review of Clinical Pharmacology
JF - Expert Review of Clinical Pharmacology
IS - 1
ER -